SOMERSET, N.J. - Catalent, Inc. (NYSE ... has reached a definitive agreement to divest its Somerset, New Jersey oral solids development and small-scale manufacturing facility.

Ardena inks agreement to acquire Catalent’s state-of-the-art facility in Somerset, New Jersey: Ghent, Belgium Tuesday, October 15, 2024, 16:00 Hrs [IST] Ardena, a specialist pha ...

Catalent, Inc. , the leader in enabling the development and supply of better treatments for patients worldwide, today issued the following open letter to customers: To Catalent's Valued Customers, I ...

Johnson & Johnson, a global health care and medtech company based in New Jersey, plans to invest more than $2 billion ... Fresenius Kabi, Grifols, Catalent, Merck, Novo Nordisk, Pfizer and Thermo ...

It is home to established life sciences companies such as CMP Pharma, Fresenius Kabi, Grifols, Catalent, Merck ... a global health care and medtech company based in New Jersey, plans to invest more ...

Catalent (CTLT) issued the following open letter to customers: “I want to correct a few key inaccuracies that have been reported in the ...

Catalent president and CEO Alessandro Maselli said on Monday he will stay on as the contract drugmaker's chief after it is ...

The site also serves as an oral solids development and small-scale manufacturing facility for the pharmaceutical company, ...

Catalent, a leading contract drug manufacturer, issued an open letter Monday to reassure customers that a proposed $16.5 ...

Alessandro Maselli will remain president and CEO of Catalent (NYSE:CTLT) after its acquisition by Novo Holdings, according to an open letter to customers. In the letter addressing customers, Maselli ...